1[1]Vogelstein B, Kinzler KW. P53 function and dysfunction. Cell,1992,70:523
2[2]Malkln D, Chilton-MacNeill S, Meister LA, et al. Tissue-specific expression of SV40 in tumors associated with the Li-Fraumeni syndrome. Oncogene,2001,20:4441
3[3]Chow WH, Gndley G, Mellemkiear L, et al. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control,1995,6:9
4[4]Chen PL, Chen Y, Bookstein R, et al. Genetic mecharusms of tumor suppression by the human P53 gene. Science, 1990,250:1576
5[1]Sigurgeirsson B,Lindelof B,Edhag O,Allander E.Risk of cancer in patients with dermatomyositis or polymyositis.A population-based study.N Engl J Med 1992; 326:363-367
6[2]Hill CL,Zhang Y,Sigurgeirsson B,Pukkala E,Mellemkjaer L,Airio A,Evans SR,Felson DT.Frequency of specific cancer types in dermatomyositisand polymyositis:a populationbased study.Lancet 2001; 357:96-100
7[3]Wong KO.Dermatomyositis:a clinical investigation of twenty-three cases in Hong Kong.Br J Dermatol 1969; 81:544-547
8[4]Gray RG,Altman RD,Gottlieb NL.Aberrant serum enzyme patterns in dermatomyositis associated with hepatoma.J Rheumatol 1976; 3:227-232
10[6]Gomez A,Solans R,Simeon CP,Selva A,Garcia F,Fonollosa V,Vilardell M.Dermatomyositis,hepatocarcinoma,and hepatitis C:comment on the article by Weidensaul et al.Arthritis Rheum 1997; 40:394-395
